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Introduction
Muscular dystrophies are a heterogeneous group of inherited diseases that cause progressive muscle weakness. The association of epilepsy with some of these diseases has been previously described and has most commonly been found with Fukuyama-type muscular dystrophy due to alterations in cerebral neuronal migration [1] . Among the muscular dystrophies, the limb-girdle muscular dystrophies (LGMD) compose the fourth most common group, with a prevalence of 1.63 per 100,000 individuals [2] . The diseases included in this group share a common phenotype consisting of a progressive weakness of the scapular and pelvic girdles that begins after two years of age and can be accompanied by different degrees of elevation in creatine kinase (CK) and by various anatomopathological findings. The LGMDs are divided into LGMD1 and
LGMD2 according to whether the inheritance is dominant or recessive, respectively.
LGMD2A, which is caused by a deficiency of the calpain-3 protein due to mutations in the CAPN3 gene, is the most common form of LGMD in Europe and America [2] . Its association with epilepsy has been described in only two isolated cases [1, 3] . Here, we describe a family in which a case of
LGMD2A is combined with cases of epilepsy with a genetic generalized epilepsy (GGE) phenotype in the context of a CAPN3 mutation. Figure 1 shows the pedigree of the family. We performed genetic studies on the third generation.
Clinical cases
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A C C E P T E D M A N U S C R I P T He has not presented with epileptic seizures thus far. He is homozygous for the frameshift mutation c.2362_2363delinsTCATCT in exon 22 of the CAPN3 gene.
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Other members of the family:
Subjects 5, 6, and 7-the father, paternal aunt, and paternal grandfather of the previously described subjects, respectively-present with epilepsy.
However, we do not have other clinical or genetic data for these subjects.
Discussion
LGMD2A, or calpainopathy, is a limb-girdle muscular dystrophy that, until now, had been associated with epilepsy in only two cases [1, 3] . The first case was a 12-year-old boy with the LGMD phenotype in whom a partial calpain deficiency was found by a Western blot of muscle protein; at age 7, the boy developed typical absence seizures with generalized spike-wave discharges at 3 Hz on the EEG and was treated with ethosuximide, which provided good seizure control.
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The boy had no family history of epilepsy, but two of his sisters displayed muscle involvement [1] . The second case was a 14-year-old girl with clinical signs of girdle muscle weakness and two heterozygous mutations in the CAPN3 gene (a missense A2288G mutation and a 100delG deletion in codon 763); at the age of 13, she had suffered an absence seizure and showed typical generalized epileptiform discharges on an EEG. The girl was successfully treated with VPA. In this case, the patient's sister also presented with epilepsy with absence seizures and GTCSs but did not experience muscle involvement and did not undergo genetic analysis [3] . Here, we have described several members of a family with a mutation in the CAPN3 gene that gives rise to the
LGMD2A phenotype in a single homozygous subject and is also associated with epilepsy in several family members, including two subjects who are heterozygous for the known mutation. The epilepsy of these two subjects can be framed within the context of GGE: one subject displays a clear JME phenotype, and the other subject displays GGE with isolated GTCSs and a benign evolution. The mutation present in this family (frameshift c.2362_2363delinsTCATCT in exon 22) has been previously described [4] . It is possible that the coexistence of the mutations in the CAPN3 gene and the development of epilepsy is coincidental. However, there are some data that suggest a possible relationship. On one side, the subjects with epilepsy and an alteration in the CAPN3 gene have in common the phenotype of a particular epileptic syndrome, GGE. In addition, among the subjects studied through genetic analysis, the only one who has not developed epilepsy does not have a heterozygous mutation. These two findings, although they are not direct
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evidence, suggest a possible relationship between alterations in CAPN3 and the development of GGE.
GGE is the most common group of genetically determined epilepsies, accounting for 15-20% of all epilepsies [5] . However, none of the genes usually involved in monogenic epilepsies seem to play a major role in GGE, probably indicating an oligo-polygenic predisposition for GGE and therefore a complex inheritance [6] . Along with a complex inheritance involving multiple genetic factors, environmental factors probably also play a role in GGE development, which can lead to the existence of phenotypic variations in members of the same family [6] . This could be the case for the family studied in the present work in which we observed different GGE phenotypes, from a JME phenotype to a GGE phenotype with GTCSs and a benign evolution that remains in remission without treatment. Within the genetic complexity of GGE, susceptibility variants have been observed at different loci [6] . Thus far, it has not been demonstrated that the 15q15.1 region-the location of the CAPN3 gene that encodes calpain-3 and is responsible for LGMD2A when mutated-is related to the development of genetic epilepsy. Calpain-3 is a calciumdependent protease located mainly in mammalian skeletal muscle; however, the presence of calpain-3 mRNA has also been demonstrated in other tissues, including the brain, and in cells with a neuronal phenotype [7, 8] . The activation of calpain by the influx of intracellular calcium through NMDA receptors cleaves the GluR1 domain of AMPA receptors, resulting in an inhibition of excitatory ion currents [9] ; this regulatory function of AMPA receptors could be altered in patients with mutations in CAPN3 and could thus be related to the pathophysiology of epilepsy. However, there is currently no clear evidence
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regarding the possible role of calpain-3 in epilepsy, particularly at the level of the central nervous system, and thus far reports linking the deficit of this protein and the development of LGMD2A with epilepsy are rare. Therefore, future reports of new cases and an expansion of the body of knowledge regarding calpain-3 physiology and the genetics of GGE are necessary to further explore this relationship.
Conclusions
We have presented a unique case of a family in which LGMD2A is associated with GGE. We believe it is important to report all cases that relate these two conditions to elucidate their possible association and to verify the hypothesis that mutations in CAPN3 may be some of the multiple predisposing factors related to the complex genetic basis of GGE. 
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